MA-WATERS-CORPORATION
22.3.2022 13:02:10 CET | Business Wire | Press release
Waters Corporation (NYSE:WAT) today introduced new software and analytical columns to aid biomolecule drug discovery and development. The new Waters™ Intact Mass app on waters_connect™ allows scientists using the BioAccord™ LC-MS System to confirm the mass of biomolecules and impurities made by synthetic or recombinant processes nearly twice as fast as other commercially available options.i
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005136/en/
“Acquiring mass and purity data of biomolecules is time consuming. Skilled analysis of complex mass spectrometry data is required, typically in remote specialist analytical laboratories,” said Jon Pratt, Waters Division Senior Vice President, Waters Corporation. “The new Waters Intact Mass App enables bioengineers and biochemists to accelerate drug discovery and development with simplified technology to generate mass confirmation data on their own in minutes/hours instead of days/weeks.”
Intact mass analysis is routinely performed during all stages of the development of biological drugs including proteins, peptides, oligonucleotide therapies and conjugates. In early stages of drug discovery, biochemists must analyze hundreds or even thousands of different samples per week. To help speed this process, the Waters Intact Mass app provides a fast, reliable, and automated solution to facilitate mass confirmation and purity determination of novel biotherapeutics. The application features intelligent automated deconvolution to process sample results within minutes of their capture, with minimal user input.
Introducing Waters MaxPeak Premier Protein BEH C4 300Å Columns for Intact & Subunit Protein Analyses
Complementing the introduction of the Intact Mass app is a new line of analytical columns that are essential for analyzing intact biomolecules and their subunits. The ACQUITY™ Premier and XBridge™ Premier Protein BEH C4 300Å Columns for the BioAccord LC-MS System feature MaxPeak High Performance Surfaces (HPS) technology that prevents the loss of sample analytes due to adsorption of phosphorylated and carboxylated molecules between the sample and metal surfaces of both the LC system and column. This enables up to 3X greater sensitivity for low-level intact mass analysis and 2X greater sensitivity for the intact mass analysis of phosphorylated proteins and low-level subunits of monoclonal antibodies.ii
The Intact Mass App on waters_connect is available for new BioAccord LC-MS Systems and as an upgrade to previously installed systems. MaxPeak Premier Protein BEH C4 300Å Columns are now available from Waters worldwide.
Additional Resources
- Read the blog post: Automating Intact Mass Deconvolution: It’s About Time
- See our application note: Intact Mass – A Versatile waters_connect Application for Rapid Mass Confirmation and Purity Assessment of Biotherapeutics
- Follow and connect with Waters via LinkedIn , Twitter , and Facebook
About Waters Corporation (www.waters.com )
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in more than 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters, BioAccord, ACQUITY, Premier, UPLC, XBridge, MaxPeak, and waters_connect are trademarks of Waters Corporation.
_____________________
i
Estimate based on obtaining the results for 96 samples using a Waters BioAccord System and Intact Mass parallel acquisition and processing approach as compared to the “acquire then process” workflow of commercially available offerings.
ii Based on a comparison of MaxPeak Premier Protein BEH C4 300Å Columns with stainless steel ACQUITY Protein 300Å Columns
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322005136/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom